Charles River Laboratories
CRL
$181.34
+10.24%
Charles River Laboratories International, Inc. is a leading global provider of essential products and services to accelerate the drug discovery and development process, operating within the Medical - Diagnostics & Research industry. The company is a market leader and critical partner to pharmaceutical and biotechnology firms, with distinct competitive advantages through its integrated portfolio spanning research models, discovery services, safety assessment, and manufacturing support. The current investor narrative is dominated by a volatile earnings story, as evidenced by recent sharp price swings, with attention focused on the company's ability to navigate a challenging biotech funding environment and its recovery from a significant Q4 2025 net loss, which has introduced uncertainty around near-term profitability and growth stability.…
CRL
Charles River Laboratories
$181.34
Investment Opinion: Should I buy CRL Today?
Rating: Hold. The core thesis is that CRL is a fundamentally challenged company trading at a cyclically depressed valuation, creating a high-risk, high-potential-reward situation that currently favors waiting for clearer signs of a turnaround.
Supporting evidence includes a forward P/E of 12.9x, which is reasonable if earnings recover as analysts project (avg. EPS $15.30). However, this is juxtaposed against negative trailing profitability (net margin -3.6%), declining revenue (Q4 YoY -0.83%), and severe price momentum (YTD -21.52%). The valuation at a PS of 2.51x is at multi-year lows, suggesting much bad news is priced in, but the strong free cash flow generation provides a tangible financial floor.
The thesis would upgrade to Buy on two conditions: 1) a confirmed reversal in quarterly revenue growth to positive territory, and 2) a sustained recovery in gross margins above 33%. It would downgrade to Sell on a breakdown below the $132.58 support level on high volume, signaling a failure of the valuation floor. Relative to its own history, the stock is undervalued, but relative to its near-term fundamentals, it appears fairly valued given the high uncertainty. The current Hold recommendation balances the deep value opportunity against the substantial execution and cyclical risks.
Sign up to view all
CRL 12-Month Price Forecast
CRL presents a classic 'show me' story. The market has severely punished the stock for its earnings volatility, compressing its valuation to levels that could be attractive if a recovery unfolds. However, the burden of proof is squarely on management to demonstrate stabilizing revenues and a return to sustainable profitability. The neutral stance reflects this balance: the downside appears somewhat protected by valuation and cash flow, but the upside is contingent on a fundamental turnaround that remains uncertain. The stance would upgrade to bullish on a confirmed quarterly earnings beat with positive guidance; it would turn bearish on a breakdown below the $132.58 support level.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Charles River Laboratories's 12-month outlook, with a consensus price target around $235.74 and implied upside of +30.0% versus the current price.
Average Target
$235.74
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$145 - $236
Analyst target range
Analyst coverage for CRL appears limited in the provided dataset, with only 5 analysts providing estimates for revenue and EPS. The institutional ratings data shows a mix of opinions among covering firms, with recent actions including 'Buy' from TD Cowen and Citigroup, 'Overweight' from Barclays, 'Outperform' from Evercore ISI, and 'Neutral' from UBS, Mizuho, and JP Morgan. This distribution suggests a consensus that leans cautiously optimistic or neutral, but a formal consensus recommendation and average price target are not provided in the data, preventing a calculation of implied upside/downside. The range of analyst estimates provides some signal: estimated EPS for the forward period averages $15.30, with a low of $14.97 and a high of $16.13, a relatively tight range indicating consensus on earnings recovery. Revenue estimates average $4.25 billion. The lack of a published price target range in the data, however, limits the analysis of bull and bear cases. The recent pattern of institutional ratings shows no downgrades in the provided sample, with actions in February 2026 largely reiterating existing ratings. This suggests analysts are in a 'wait-and-see' mode following the volatile Q4 results, maintaining their theses but not yet expressing heightened conviction either way.
Bulls vs Bears: CRL Investment Factors
The evidence currently tilts bearish, driven by severe fundamental deterioration in revenue growth and profitability, coupled with persistent negative price momentum. The bull case rests on valuation compression, strong cash flow, and an expected earnings recovery, but these are forward-looking hopes rather than current realities. The single most important tension in the investment debate is the timing and certainty of the forecasted earnings normalization. If CRL can swiftly return to the profitability implied by its forward P/E of 12.9x, the stock is deeply undervalued. However, if revenue declines persist and margin pressure continues, the earnings recovery will be delayed, justifying the current depressed valuation and potentially leading to further downside.
Bullish
- Strong Free Cash Flow Generation: Despite earnings volatility, the company generates robust cash flow, with TTM free cash flow of $518.5 million. This provides a significant financial cushion to navigate the current biotech funding environment, service debt, and fund operations without external financing pressure.
- Valuation at Multi-Year Lows: The stock trades at a PS ratio of 2.51x, a dramatic compression from historical levels above 10x in early 2024 and over 25x in 2021. This places the stock near the bottom of its own valuation band, potentially pricing in excessive pessimism regarding its long-term prospects.
- Analyst Consensus on Earnings Recovery: Analysts forecast a sharp earnings rebound, with a forward P/E of 12.9x based on an average EPS estimate of $15.30. The tight range between the low ($14.97) and high ($16.13) estimates indicates consensus that the substantial Q4 2025 net loss of -$276.6M is non-recurring.
- Solid Balance Sheet & Liquidity: The company maintains a manageable debt-to-equity ratio of 0.97 and a current ratio of 1.29. Combined with strong operating cash flow ($147.5M in Q4), this provides financial stability and reduces near-term solvency risk despite the volatile earnings profile.
Bearish
- Severe Earnings Volatility & Recent Loss: Q4 2025 reported a massive net loss of -$276.6M (net margin -27.8%), a stark reversal from Q3 net income of $54.4M. This extreme volatility and negative profitability introduce significant uncertainty around the company's near-term operational stability and cost control.
- Revenue Decline & Growth Stall: Q4 2025 revenue of $994.2M declined 0.83% YoY, marking the second consecutive quarterly decline from a Q2 2025 peak of $1.03B. This indicates fundamental softness, likely driven by constrained biotech funding, challenging the company's growth narrative.
- Persistent Negative Momentum & High Beta: The stock is in a pronounced downtrend, down 21.52% YTD and underperforming the S&P 500 by -30.44% YTD. With a beta of 1.45, it exhibits 45% higher volatility than the market, amplifying downside moves during periods of fundamental weakness and risk-off sentiment.
- Margin Compression Across Key Metrics: Gross margin compressed to 30.96% in Q4 from 33.7% in Q3, while operating margin fell to 12.1% from 13.3%. This pressure on profitability, even excluding the large one-time loss, suggests underlying operational challenges with pricing or cost absorption.
CRL Technical Analysis
The stock is in a pronounced downtrend from its recent highs, trading near the lower end of its 52-week range. With a current price of $158.86, it sits approximately 30.6% below its 52-week high of $228.88 and only 19.8% above its 52-week low of $132.58, indicating it is in a zone of potential value but also significant technical weakness. The 1-year price change of +17.69% is misleading as it captures a recovery from an even lower base, while the more recent 6-month and YTD changes of -5.24% and -21.52%, respectively, confirm the prevailing negative momentum. Recent momentum is decisively negative and accelerating, diverging sharply from the positive longer-term 1-year trend. The stock has declined 13.24% over the past month and 5.96% over the past three months, underperforming the S&P 500 by -18.73% and -13.69% over the same periods, respectively. This severe underperformance, coupled with a beta of 1.45 indicating the stock is 45% more volatile than the market, suggests the stock is experiencing high-risk, aggressive selling pressure, likely driven by fundamental disappointments rather than a simple market correction. Key technical levels are clearly defined, with major support at the 52-week low of $132.58 and immediate resistance at the recent recovery high near $185 from early May. A breakdown below the $132.58 support would signal a continuation of the downtrend and potentially trigger further technical selling. Conversely, a sustained move above the $185 resistance would be necessary to suggest the downtrend is abating. The stock's high beta of 1.446 confirms its status as a high-volatility name, which investors must factor into position sizing and risk management, especially during periods of fundamental uncertainty.
Beta
1.45
1.45x market volatility
Max Drawdown
-33.9%
Largest decline past year
52-Week Range
$133-$229
Price range past year
Annual Return
+33.1%
Cumulative gain past year
| Period | CRL Return | S&P 500 |
|---|---|---|
| 1m | +8.7% | +6.0% |
| 3m | +1.6% | +10.0% |
| 6m | +1.8% | +10.4% |
| 1y | +33.1% | +28.4% |
| ytd | -10.4% | +10.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CRL Fundamental Analysis
Revenue growth has stalled and turned slightly negative, indicating near-term pressure. The most recent Q4 2025 revenue was $994.2 million, representing a year-over-year decline of 0.83%. Examining the quarterly sequence for fiscal 2025 shows revenue peaked in Q2 at $1.03 billion and has since declined for two consecutive quarters to the Q4 level, suggesting a decelerating trend. Segment data from the latest period shows Discovery and Safety Assessment ($591.6M) as the largest driver, but the overall trend implies softness across the portfolio, likely reflecting a constrained biotech funding environment impacting client spending. Profitability is highly volatile and currently negative, with significant margin compression evident in the latest quarter. Q4 2025 reported a substantial net loss of -$276.6 million, translating to a net margin of -27.8%, a stark contrast to the profitable Q3 2025 which had net income of $54.4 million and a net margin of 5.4%. The gross margin of 30.96% in Q4 is below the levels seen in prior 2025 quarters (e.g., 33.7% in Q3), indicating pressure on pricing or cost absorption. The operating margin of 12.1% in Q4, while positive, is down from 13.3% in Q3, showing compression at the operating level as well. The balance sheet shows moderate leverage and the company continues to generate solid operating cash flow, supporting financial health. The debt-to-equity ratio is 0.97, indicating a balanced capital structure. More importantly, the company generated $147.5 million in operating cash flow in Q4 2025 and has trailing twelve-month free cash flow of $518.5 million, demonstrating its ability to convert sales into cash. The current ratio of 1.29 provides adequate short-term liquidity. The strong free cash flow generation provides a cushion to manage debt, fund operations, and navigate the current period of earnings volatility without immediate external financing needs.
Quarterly Revenue
$994227000.0B
2025-12
Revenue YoY Growth
+0.00%
YoY Comparison
Gross Margin
+0.30%
Latest Quarter
Free Cash Flow
$518494000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CRL Overvalued?
Given the negative net income in the most recent quarter, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is 2.51x. A forward-looking perspective is available via the EV/Sales multiple of 2.59x, which aligns closely with the PS ratio, suggesting the market is not pricing in significant sales multiple expansion in the near term. The gap between the negative trailing P/E of -69.93x and the forward P/E of 12.91x is dramatic, reflecting the market's expectation that the large Q4 loss is non-recurring and that profitability will normalize sharply in the coming year. Compared to industry averages, data is not available in the provided dataset to make a precise sector comparison for the PS or EV/Sales multiples. However, the forward P/E of 12.9x, if achieved, would likely be evaluated against life science tools and services peers. Without a specific benchmark, the assessment focuses on the stock's own historical context to gauge relative valuation. Historically, the stock's own valuation has compressed significantly from pandemic-era highs. The current PS ratio of 2.51x is substantially below the historical PS ratios observed in the data, which were above 10x as recently as early 2024 and reached over 25x in 2021. This places the stock near the bottom of its own multi-year valuation band. This compression suggests the market has already priced in a significant deterioration in growth prospects and profitability concerns. Trading at these depressed historical levels may indicate a value opportunity if the company's fundamentals stabilize, but it also reflects justified skepticism about its near-term earnings power.
PE
-69.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -11x~77x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are centered on extreme earnings volatility and margin pressure. The Q4 2025 net loss of -$276.6M and consecutive quarterly revenue declines demonstrate high operational sensitivity to the biotech funding cycle. While strong free cash flow ($518.5M TTM) mitigates liquidity risk, the debt-to-equity of 0.97 means leverage amplifies equity volatility. The core risk is that the forecasted EPS recovery to $15.30 fails to materialize due to persistent client spending softness, turning the current depressed valuation into a value trap.
Market & Competitive Risks are heightened by the stock's high beta of 1.45, which magnifies its underperformance during market downturns, as seen in its -30.44% YTD relative performance. Trading at a PS ratio of 2.51x, a fraction of its historical multiples, suggests the market has already priced in significant derating. However, further compression is possible if sector-wide multiples contract or if competitors gain share in a constrained funding environment. The lack of a dividend (0% yield) offers no income cushion during this volatile period.
The Worst-Case Scenario involves a continuation of the current downtrend fueled by another earnings miss, leading to a breakdown of key technical support at the 52-week low of $132.58. In this scenario, analyst optimism evaporates, the forward P/E multiple expands as earnings estimates are cut, and the stock re-tests its lows. From the current price of $158.86, a drop to the 52-week low represents a realistic downside of approximately -16.5%. A more severe drawdown, approaching the stock's maximum historical drawdown of -33.88%, could see prices fall toward $105, a loss of over -34% from current levels, though this would require a fundamental crisis beyond current visibility.
FAQ
The key risks are, in order of severity: 1) Fundamental Deterioration Risk: Continued revenue declines and failure to achieve the forecasted EPS recovery of $15.30, as evidenced by the Q4 2025 net loss of -$276.6M. 2) Market & Sentiment Risk: The stock's high beta of 1.45 magnifies losses during market downturns, and its severe underperformance (YTD -21.5% vs. SPY) reflects overwhelmingly negative sentiment. 3) Cyclical Demand Risk: The company's revenue is highly sensitive to biotech R&D funding, which remains constrained. 4) Operational Risk: Margin compression, with Q4 gross margin falling to 30.96%, indicates potential pricing pressure or inefficiencies.
The 12-month forecast is bifurcated, with a base case target range of $165-$195 (55% probability), a bull case of $210-$240 (25%), and a bear case of $132-$150 (20%). The base case, which is most likely, assumes the company's earnings recover in line with analyst consensus (~$15.30 EPS) but that revenue growth remains tepid, preventing a major valuation re-rating. The key assumption is that the large Q4 2025 loss is an anomaly. The forecast hinges entirely on the company's ability to stabilize its top line and demonstrate consistent profitability in the coming quarters.
CRL's valuation sends mixed signals. Based on trailing fundamentals, with negative earnings and declining revenue, the stock could be considered fairly valued or even overvalued. However, on a forward-looking basis, the forward P/E of 12.9x suggests the market is pricing in a significant earnings recovery. Most notably, the Price-to-Sales ratio of 2.51x is dramatically below its historical levels above 10x, indicating the stock is deeply undervalued relative to its own history. This compression implies the market has priced in a severe deterioration in growth prospects. The verdict is that CRL is relatively undervalued from a long-term historical perspective, but this discount is justified by near-term fundamental weakness.
CRL is a high-risk, potentially high-reward stock that is not a good buy for conservative investors. For aggressive investors with a long-term horizon and high risk tolerance, it may represent a compelling deep-value opportunity if they believe in the analyst forecast for an earnings recovery to an EPS of $15.30. The stock trades at a forward P/E of 12.9x, which is reasonable, and a PS ratio of 2.51x, near multi-year lows. However, the substantial downside risks include persistent revenue declines, margin pressure, and the stock's high beta of 1.45. It is a good buy only for those willing to withstand significant volatility while waiting for a fundamental turnaround that is not yet guaranteed.
CRL is unsuitable for short-term trading due to its high volatility (beta 1.45) and lack of clear near-term catalysts. It does not pay a dividend, eliminating an income rationale. The investment case is fundamentally a long-term turnaround story, requiring patience to see if the company can navigate the current biotech funding cycle and return to sustainable growth. Given the deep valuation compression and the time needed for operational execution, a minimum holding period of 2-3 years is suggested to allow the thesis to play out. It is best suited for a long-term, strategic allocation within a diversified portfolio for investors who can tolerate significant interim price swings.